Overview

Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients

Status:
Unknown status

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the PK of AP-CD/LD given at dose of 50/500mg three times daily compared to CD/LD immediate release (Sinemet) 1.5 tablets of dose of 25/100 given 5 times per day in Parkinson's Disease patients.

Phase:

Phase 2

Details

Lead Sponsor:

Intec Pharma Ltd.

Treatments:

Carbidopa
Carbidopa, levodopa drug combination
Levodopa